Abiopharma

🔍 Schmitt Thomas N (Executive)

Company: Skyward Specialty Insurance Group, Inc. (SKWD)

Report Date: 2026-05-06

Detailed Transactions and Holdings:

• Acquired 3,358 shares of Common Stock (Direct)
  Date: 2026-05-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 19,881.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,322 shares of Common Stock at $43.68 per share (Direct)
  Date: 2026-05-06 | Code: F | equity_swap_involved: 0 | shares_owned_after: 18,559.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 2,525 shares of 2023 LTIP - PSUs (Derivative)
  Date: 2026-05-06 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F4, F4

Footnotes:

• F1: Represents the number of shares that were acquired by the Reporting Person in connection with the settlement of the Performance Share Units ("PSUs") listed in Line I of Table II.
• F2: The disposition reported on this Form 4 represents shares withheld to cover tax withholding obligations in connection with the vesting and settlement of the PSUs listed in Line I of Table II. The disposition is mandated by the Issuer and does not represent a discretionary transaction by the Reporting Person.
• F3: Each PSU represents the right to receive one share of the Issuer's Common Stock upon settlement.
• F4: On February 27, 2023, the Reporting Person was awarded 2,525 PSUs. The PSUs are subject to obtaining specified performance criteria from January 1, 2023 through December 31, 2025. The number of PSUs subject to vest under this award can range from 0% to 150% of the amount shown. This award fully vested on December 31, 2025 and settled upon certification by the Compensation Committee of the Board of Directors.